The effect of timing of teriparatide treatment on the circadian rhythm of bone turnover in postmenopausal osteoporosis

被引:38
|
作者
Luchavova, Maria [1 ,3 ]
Zikan, Vit [1 ,3 ]
Michalska, Dana [1 ,3 ]
Raska, Ivan, Jr. [1 ,3 ]
Kubena, Ales A. [2 ]
Stepan, Jan J. [4 ]
机构
[1] Gen Univ Hosp Prague, CZ-12808 Prague, Czech Republic
[2] Acad Sci Czech Republic, Inst Informat Theory & Automat, CZ-18208 Prague, Czech Republic
[3] Charles Univ Prague, Dept Internal Med 3, Dept Endocrinol & Metab, Fac Med 1, CZ-12808 Prague, Czech Republic
[4] Charles Univ Prague, Inst Rheumatol, Fac Med 1, CZ-12808 Prague, Czech Republic
关键词
INTACT PARATHYROID-HORMONE; SERUM CORTISOL; DIURNAL RHYTHM; GROWTH-HORMONE; IN-VIVO; RESORPTION; OSTEOPROTEGERIN; CALCIUM; ABNORMALITIES; OSTEOCALCIN;
D O I
10.1530/EJE-10-1108
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: We hypothesized that with the administration of teriparatide (TPTD) treatment at different times, we would be able to modify the physiological circadian rhythm of bone turnover. Methods: The concentration of serum C-terminal telopeptide of collagen type I (beta CTX), serum N-terminal propeptide of procollagen type I (P1NP), serum ionized calcium (iCa), and plasma PTH were measured every 3 h over a 24 h period in 14 postmenopausal osteoporotic women (aged 72.4 +/- 9.3 years) treated with 20 mu g TPTD for long term, given at different times of the day. General linear model-repeated measurements (GLM RM) were performed to analyze the circadian rhythms as well as intergroup comparisons. Results: GLM-RM for both related groups showed a significant influence of time of day on all measured variables except P1NP. The analysis for each group separately provided a powerful model for beta CTX (P < 0.001, eta(2) = 0.496), serum iCa (P < 0.001, eta(2) = 0.423), plasma PTH (P < 0.001, eta(2) = 0.283), and serum PINP (P < 0.001, eta(2) = 0.248). While the evening TPTD treatment showed a marked circadian rhythm for serum beta CTX, the morning TPTD treatment rather suggested circasemidian rhythm. The P1NP rhythm followed a much smaller amplitude of the rhythm than beta CTX. Changes in serum iCa were positively related to changes in serum beta CTX (P < 0.001) and negatively related to changes in PTH (P < 0.001). Conclusion: Timing of TPTD administration may significantly change the 24 h variation in bone turnover markers as well as calcium-parathyroid axis in postmenopausal osteoporotic women.
引用
收藏
页码:643 / 648
页数:6
相关论文
共 50 条
  • [21] Use of bone turnover markers in postmenopausal osteoporosis
    Eastell, Richard
    Szulc, Pawel
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (11): : 908 - 923
  • [22] OSTEOPROTEGERIN, RANKL AND BONE TURNOVER IN POSTMENOPAUSAL OSTEOPOROSIS
    Jabbar, S.
    Drury, J.
    Fordham, J.
    Datta, H.
    Francis, R.
    Tuck, S.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : S271 - S271
  • [23] Adrenal effects of teriparatide in the treatment of severe postmenopausal osteoporosis
    A. Lasco
    A. Catalano
    N. Morabito
    A. Gaudio
    G. Basile
    A. Trifiletti
    M. Atteritano
    Osteoporosis International, 2011, 22 : 299 - 303
  • [24] Bone turnover markers in the management of postmenopausal osteoporosis
    Brown, Jacques P.
    Albert, Caroline
    Nassar, Bassam A.
    Adachi, Jonathan D.
    Cole, David
    Davison, K. Shawn
    Dooley, Kent C.
    Don-Wauchope, Andrew
    Douville, Pierre
    Hanley, David A.
    Jamal, Sophie A.
    Josse, Robert
    Kaiser, Stephanie
    Krahn, John
    Krause, Richard
    Kremer, Richard
    Lepage, Raymond
    Letendre, Elaine
    Morin, Suzanne
    Ooi, Daylily S.
    Papaioaonnou, Alexandra
    Ste-Marie, Louis-Georges
    CLINICAL BIOCHEMISTRY, 2009, 42 (10-11) : 929 - 942
  • [25] Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis
    Jabbar, Suhair
    Drury, John
    Fordham, John N.
    Datta, Harish K.
    Francis, Roger M.
    Tuck, Stephen P.
    JOURNAL OF CLINICAL PATHOLOGY, 2011, 64 (04) : 354 - 357
  • [26] Bone marker variations in postmenopausal women with osteoporosis treated with teriparatide
    Barata, S.
    Osorio, F.
    Pauleta, J.
    Santo, S.
    Neves, J.
    Pereira-Coelho, A.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S342 - S342
  • [27] The Effect of Denosumab on Bone Turnover Markers (BTM) in Postmenopausal Women With Osteoporosis
    Cummings, Steven
    Wang, Andrea
    San Martin, Javier
    McClung, Mike
    Claus, Christiansen
    Libanati, Cesar
    Siris, Ethel
    Eastell, Richard
    BONE, 2010, 46 : S28 - S28
  • [28] ANABOLIC BONE WINDOW WITH WEEKLY TERIPARATIDE THERAPY IN POSTMENOPAUSAL OSTEOPOROSIS
    Bhadada, S. K.
    Gopalaswamy, V.
    Dhibar, D. P.
    Gupta, V.
    Khandelwal, N.
    Bhansali, A.
    Garg, S.
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 : S761 - S761
  • [29] ANABOLIC BONE WINDOW WITH WEEKLY TERIPARATIDE THERAPY IN POSTMENOPAUSAL OSTEOPOROSIS
    Abate, Ejigayehu G.
    ENDOCRINE PRACTICE, 2017, 23 (06) : 745 - 746
  • [30] A CIRCADIAN-RHYTHM OF SERUM OSTEOCALCIN LEVELS IN POSTMENOPAUSAL OSTEOPOROSIS
    PIETSCHMANN, P
    RESCH, H
    WOLOSZCZUK, W
    WILLVONSEDER, R
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1990, 20 (03) : 310 - 312